Lipitor Lawsuits in MDL Surge to 700 Filings, More Expected in Coming Months

Lipitor Lawsuits in MDL Surge to 700 Filings, More Expected in Coming Months

More than 700 Lipitor lawsuits have joined the ongoing multidistrict litigation (MDL) filed against Pfizer, which is currently underway in the U.S. District Court, District of South Carolina (In Re: Lipitor (Atorvastatin Calcium) Marketing, Salespractices and Products Liability Litigation (No. II), MDL 2502). Since February 2014 when the U.S. Judicial Panel on MDL issued the transfer order to set up these cases, the number of Lipitor lawsuits filed against Pfizer has increased by more than 12 times, surging from 56 in February 2014 to more than 700 in May 2014.

While more than 700 Lipitor lawsuits have joined the MDL against Pfizer, some experts expect the filings to exceed 10,000 by the time the first of these cases go to trial.

While more than 700 Lipitor lawsuits have joined the MDL against Pfizer, some experts expect the filings to exceed 10,000 by the time the first of these cases go to trial.

Some of legal experts who are closely monitoring this litigation expect that these numbers will continue to grow in the coming months, with some estimating the total number of Lipitor lawsuits to exceed about 10,000 filings by the time the first cases in this MDL eventually go to trial.

Lipitor MDL: Allegations against Pfizer

The plaintiffs in the ongoing Lipitor MDL are all women who are alleging that their use of Lipitor (atorvastatin calcium) caused them to develop type-2 diabetes (in fact, research has indicated that women are about 7 times more likely to develop type-2 diabetes when using Lipitor than men are due to the different way in which females’ bodies metabolize this drug).

Additional allegations included in these Lipitor lawsuits are contending that Pfizer:

  • Failed to test the safety of its cholesterol-lowering drug Lipitor
  • Knew about the serious risks of developing type-2 diabetes when taking this drug and, yet, did not properly warn the public about these risks
  • Continued to downplay the serious risks associated with Lipitor use even after adding warnings to the drug labels (Court documents specifically call Pfizer’s Lipitor warnings “insufficient” and “nonsensical”).

At this point, plaintiffs’ attorneys expect that these Lipitor lawsuits will be on the fast track to resolution, as the Honorable Richard M. Gergel who has been appointed to preside over this litigation has expressed his intentions of getting the first cases in this MDL underway as soon as July 2015.

Whether Pfizer will attempt to settle these cases before trial remains to be seen.

Phoenix Dangerous Drug Lawyers at the Law Office of Richard Langerman

You have a choice in the lawyer you hire to handle your claim, and the choice you make can affect the compensation you receive. Make sure that your lawyer has the ability and experience to handle your case. If the use of Lipitor or other potentially dangerous drugs have caused you to develop serious health problems, the Phoenix product liability lawyers at the Law Office of Richard Langerman will fight to help you obtain the highest possible settlement to cover your injuries and losses.

For more than 25 years, our attorneys have been representing clients and aggressively defending their rights both inside and outside of the courtroom against defense attorneys, corporate lawyers and insurance company agents alike. In addition to having extensive experience handling dangerous drug lawsuits, our attorneys are also skilled at overseeing product liability cases, motor vehicle accident cases, insurance bad faith cases and various other types of personal injury cases.

Contact Us to Learn More about Your Rights and Case

Call us today at (602) 240-5525 to learn more about your rights and receive professional advice regarding your case by setting upa free, no obligations initial consult with our trusted attorneys.

No Comments

Sorry, the comment form is closed at this time.